|
Meet us at the GE Healthcare DiPIA meeting in Boston (June 17-20), presenting a poster with the results of our collaboration with GE Healthcare.
Salipro® for functional studies of a GPCR with NMR. Half-life of GPCR in Salipro® extended from 1.5 to 30 days. Check out the latest paper on our technology by Nietlispach et al: http://pubs.acs.org/doi/10.1021/jacs.7b06730
CEO Jens Frauenfeld invited speaker at the 10th Annual Proteins & Antibodies Congress in London.
Salipro Biotech is recipient of the Ingemar Croon Award 2017 (2 MSEK).
We're growing and moving to new premises in central Stockholm. With more lab space and offices, we're located at the Greenhouse Labs at the Royal Institute of Technology in Stockholm. Location
Stefan Geschwindner, Principal Scientist, AstraZeneca R&D Gothenburg:
“We have been impressed by the fact that Salipro Biotech is able to work both with detergent-solubilised material as well as with crude cell-membranes and furthermore demonstrated good feasibility to generate non-aggregated membrane proteins in a detergent-free form. This forms an excellent basis for the next steps that will include both structural and biophysical work.” The Salipro® technology is covered in the news (selected articles):
Breakthrough Nanoparticle Technology to Study Structure of Membrane Proteins in Lipid Environment Nanoparticles Reveal Membrane Proteins' Structure and Function Novel nanoparticle technology can decipher protein structures and help access drug targets Salipro Biotech AB receives investment from Wingefors Ventures AB.
The Salipro® technology receives the VINN Verification-for-growth grant (2 MSEK) from VINNOVA, the Swedish Innovation Agency.
|
Categories |